Should We Discontinue Anticoagulation Before TAVR?

Against what common sense dictates, continuing oral anticoagulation pre- and post- transcatheter aortic valve replacement (TAVR) is safe, according to this article soon to be published in JACC Interventions. There was no increase in hemorrhagic or vascular complications and, paradoxically, those who continued using anticoagulant agents received fewer transfusions that those who did not.

¿Es necesario suspender la anticoagulación previa al TAVI?

A significant portion of patients who undergo TAVR have a prior indication for long-term oral anticoagulation. However, as the optimal management of these patients is unknown, the information used is usually based on other procedures. Generally, oral anticoagulation is suspended the days leading to the procedure—depending on the thrombosis risk—using a bridge with low molecular weight heparin.

All consecutive patients receiving oral anticoagulation undergoing transfemoral TAVR at 5 European centers were enrolled. Anticoagulation was either stopped 2 or 4 days before TAVR, or continued throughout the procedure. The primary safety endpoint was major bleeding, while secondary efficacy endpoints included vascular complications, stroke, and mortality.

About 584 patients continued with their previous anticoagulation scheme and 733 interrupted it.


Read also: Current DES Performance: Is There Room for Improvement?


At 30 days, the major bleeding or life-threatening bleeding rate was 11.3% vs. 14.3% (odds ratio [OR]: 0.86; 95% confidence interval [CI]: 0.61 to 1.21; p = 0.39). Vascular complications were also pretty much identical among patients who continued using anticoagulation vs. those who stopped it (11% vs. 12.3%; OR: 0.89; 95% CI: 0.62 to 1.27; p = 0.52).

Transfusion was less often required in patients with continuation of anticoagulation and 12-month mortality was identical among them.

Conclusion

Continuing oral anticoagulation in patients who will undergo TAVR does not increase bleeding or vascular complications.

Original Title: Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants.

Reference: Miriam Brinkert et al. J Am Coll Cardiol Intv 2020, article in press. https://doi.org/10.1016/j.jcin.2020.09.062.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...